Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors

Conclusion.Poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in ICI compared with other trials. Clinical trial completion remains a high priority and can be influenced by provider and patient factors.Implications for Practice.Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. This study assessed factors of early terminated/withdrawn oncology trials, focusing on trials with immune checkpoint inhibitors (ICI), and found that poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in immune checkpoint inhibitor trials compared to other ...

from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2EktWTe
via IFTTT